A newly published cache of CRLs includes six novel oncology drugs.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
The company abandons TNG908, but is still all in on the troubled target.
Reports of Arc-10's failure are greatly exaggerated, the company argues.
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.